The reaffirmation of an Outperform rating and a $270 price target by a reputable analyst like Jay Olson from Oppenheimer is likely to instill confidence among investors about Biogen's future prospects. This could lead to positive sentiment in the short term, potentially driving the stock price up as investors react to the analyst's optimistic outlook.